This company has been marked as potentially delisted and may not be actively trading. NASDAQ:UROV Urovant Sciences (UROV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Urovant Sciences Stock (NASDAQ:UROV) 30 days 90 days 365 days Advanced Chart Get Urovant Sciences alerts:Sign Up Key Stats Today's Range$16.24▼$16.2450-Day Range$16.19▼$16.2452-Week Range$7.15▼$16.26VolumeN/AAverage Volume114,469 shsMarket Capitalization$531.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Read More Receive UROV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Urovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UROV Stock News HeadlinesRoivant Sciences: Booming Pipeline Without Product Revenues Creates Valuation RiddleJuly 5, 2025 | seekingalpha.comXavier Creative House Appoints Jami Rogers as VP of Sales & MarketingNovember 4, 2024 | msn.comAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking and savings account… With this better, more technologically advanced dollar. President Trump himself called it a "big innovation"… And said that this new form of currency represents "American brilliance at its best."September 15 at 2:00 AM | Brownstone Research (Ad)Xavier Creative House Hires Jami Rogers as Vice President of Sales & MarketingOctober 29, 2024 | finance.yahoo.comPierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA(vibegron) in overactive bladder syndromeApril 26, 2024 | finanznachrichten.dePierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndromeApril 26, 2024 | finance.yahoo.comA2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of DirectorsMarch 26, 2024 | finance.yahoo.comPetauri™ Elects William Fleming and James Robinson to Its Board of DirectorsDecember 6, 2023 | finance.yahoo.comSee More Headlines UROV Stock Analysis - Frequently Asked Questions How were Urovant Sciences' earnings last quarter? Urovant Sciences Ltd. (NASDAQ:UROV) released its quarterly earnings results on Thursday, February, 11th. The company reported ($1.46) EPS for the quarter, topping analysts' consensus estimates of ($1.59) by $0.13. When did Urovant Sciences IPO? Urovant Sciences (UROV) raised $150 million in an IPO on Thursday, September 27th 2018. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen acted as the underwriters for the IPO. What other stocks do shareholders of Urovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO). Company Calendar Last Earnings2/11/2021Today9/15/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:UROV CIK1740547 Webwww.urovant.com Phone44-0-20-7400-3347FaxN/AEmployees70Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.74 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-162.90% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.90) per share Price / Book-8.55Miscellaneous Outstanding Shares32,743,000Free FloatN/AMarket Cap$531.75 million OptionableNot Optionable Beta2.36 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:UROV) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Urovant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
